Comments by "SIMON TAHITI" (@positivepawpaw7564) on "NSW paramedics will not respond to non-life-threatening calls while on strike" video.

@gribbler1695 From 2012 on in-vitro studies have showed viral replication inhibition from ivermectin. Ivermectin inhibits SARS-CoV-2 replication in-vitro and thereby removes all virus within 48 hours (University of Monash) Ivermectin is anti-inflammatory with strong data showing an inhibition of both cytokine production and a key inflammation mediator. Ivermectin substantially shrinks viral load and prevents organ damage in animal models using SARS-CoV-2 or other coronaviruses. Ivermectin as a prophylactic stops viral transmission and development of COVID-19 illness in exposed persons. Ivermectin both quickens recovery and stops deterioration in people with mild or moderate COVID-19. The drug, “hastens recovery and avoidance of ICU admission and death in hospitalized patients.” Mortality in critically ill patients is reduced with ivermectin. Regions with widespread use show major reductions in fatality rates Safety, availability, and cost are unparalleled with minimal drug interactions or side effects seen over almost four decades and billions of doses of use. WHO’s List of Essential Medicines has included ivermectin for many years.
1
@gribbler1695 AAP relies heavily on the fact that the FDA and NIH, “have said that [ivermectin] is not approved for the prevention or treatment of COVID-19.” It is key to remember that official guidelines are often updated as evidence comes to light, and to rely on authority without looking at the evidence is yet another fallacy when searching for the truth. The most up-to-date (as of December 7) summary of the evidence regarding ivermectin is the FLCCC Alliance’s, “A Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” Much of the chronicling of the accumulation of evidence to date was accomplished by TrialSite. FLCCC member Dr. Pierre Kory pointed out that a good amount of reporting worldwide for this breakthrough story was in fact led by the TrialSite, an online media and information exchange platform committed to clinical trial accessibility and transparency. After all, this is necessary to nurture and build trust in research, critical in the aim to advance overall biomedical research.
1
@gribbler1695 APA Kory, P., MD, Meduri, G. U., MD, Iglesias, J., Varon, J., Berkowitz, K., MD, Kornfeld, H., MD, … Marik, P. E. (2020, November 13). Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. https://doi.org/10.31219/osf.io/wx3zn MLA Kory, Pierre, MD, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” OSF Preprints, 13 Nov. 2020. Web. Chicago Kory, Pierre, MD, G. U. Meduri, MD, Jose Iglesias, Joseph Varon, Keith Berkowitz, MD, Howard Kornfeld, MD, Eivind Vinjevoll, et al. 2020. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” OSF Preprints. November 13. doi:10.31219/osf.io/wx3zn.
1